This site is intended for health professionals only
Saturday 1 October 2016 Instagram
Share |

Call for new heart disease risk score

Call for new heart disease risk score

A new score for predicting a person’s risk of heart disease performs better than the existing test and should be recommended for use in the UK by the National Institute for Health and Clinical Excellence (NICE), say researchers in a paper published on bmj.com today.

But NICE currently recommends that doctors use a modified version of the long-established score (known as the Anderson Framingham model) to identify who should be offered statin treatment to reduce their risk of heart disease over the next 10 years.
 
In 2007, the BMJ published research showing that the new QRISK score was a more accurate measure of how many UK adults are at risk of developing heart disease and which adults are most likely to benefit from treatment compared with the Framingham model.

Now, two independent experts from the University of Oxford have compared the performance of the two scores for predicting the 10 year cardiovascular disease risk in over one million UK patients.

They tracked the progress of 1.07 million patients registered at 274 general practices in England and Wales for up to 12 years after first diagnosis of cardiovascular disease. All participants were aged between 35 and 74 at the start of the study.

They found that, on every performance measure, QRISK gave a more accurate prediction of 10 year cardiovascular disease risk compared with Framingham.

Despite some criticisms about missing data in the development of QRISK, the authors conclude QRISK performs better than the Anderson Framingham risk score in terms of identifying a high risk population for cardiovascular disease in the UK. Based on this evidence, they support the use of QRISK in favour of Anderson Framingham

Although there is a small charge for commercial use of QRISK (which is designed to ensure correct implementation and quality control with revenues going towards research, support and development), use of the software is free for academics, research, teaching, educational use and personal use.

BMJ 

Ads by Google

You are leaving www.nursinginpractice.com

You are currently leaving the Nursing in Practice site. Are you sure you want to proceed?